Aplicación sistemática de un algoritmo para el manejo lipídico en pacientes de muy alto riesgo cardiovascular. Impacto en los objetivos lipídicos

MASSON, WALTER; BARBAGELATA, LEANDRO; LEE, MARTÍN; SINIAWSKI, DANIEL; NAVARRO ESTRADA, JOSÉ LUIS; ARIAS, ANÍBAL; CAGIDE, ARTURO; PIZARRO, RODOLFO.
Rev. argent. cardiol ; 88(5): 440-447, set. 2020. tab, graf
Artículo en Español | LILACS-Express | ID: biblio-1251018

Documentos relacionados

  1. [PCSK9 inhibitors (PCSK9i), a new opportunity for cardiovascular prevention: clinical and regulatory aspects and access to therapy.]
  2. Treatment with Anti-PCSK9 Monoclonal Ab: Experience from a Lipid Clinic in Israel.
  3. Diagnostico de hipobetalipoproteinemia en un nino de 8 años?
  4. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease.
  5. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification.
  6. Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center.
  7. Anti PCSK9 Monoclonal Antibody Treatment in Elderly Patients: A Real-world Clinical Experience.
  8. Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program.
  9. Attainment of LDL-Cholesterol Goals in Patients with Previous Myocardial Infarction: A Real-World Cross-Sectional Analysis.
  10. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress.